CADX Share Price

Open 0.00 Change Price %
High 0.00 1 Day 0.00 0.00
Low 0.00 1 Week 0.00 0.00
Close 13.98 1 Month 0.00 0.00
Volume 6000 1 Year 0.00 0.00
52 Week High 3.80
52 Week Low 0.00
CADX Important Levels
Resistance 2 13.98
Resistance 1 13.98
Pivot 4.66
Support 1 13.98
Support 2 13.98
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
MU 44.31 6.39%
MU 44.31 6.39%
MU 44.31 6.39%
RIMM 13.03 0.39%
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
HLIT 3.70 25.42%
OTT 2.39 25.13%
QNST 8.90 20.76%
VRTA 4.00 19.40%
SNSS 2.56 19.07%
GCFB 0.44 18.92%
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
GMETP 0.15 -76.92%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%

Cadence Pharmaceuticals, Inc. (NASDAQ: CADX)

CADX Technical Analysis 5
As on 18th Mar 2014 CADX Share Price closed @ 13.98 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 8.05 & Strong Buy for SHORT-TERM with Stoploss of 12.08 we also expect STOCK to react on Following IMPORTANT LEVELS.
CADX Target for May
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
CADX Other Details
Segment EQ
Market Capital 302880832.00
Sector Consumer Durables Major Pharmaceuticals
Offical website
CADX Address
CADX Latest News
Interactive Technical Analysis Chart Cadence Pharmaceuticals, Inc. ( CADX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on Cadence Pharmaceuticals, Inc.
CADX Business Profile
Cadence Pharmaceuticals, Inc. (Cadence), incorporated in May 2004, is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing products principally for use in the hospital setting. The Company has rights to one product, OFIRMEV (acetaminophen) injection, an intravenous (IV), formulation of acetaminophen. The Company in-licensed the United States, and Canadian rights to OFIRMEV from Bristol-Myers Squibb Company (BMS), which sells intravenous acetaminophen in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. In January 2011, the Company launched commercial sales of OFIRMEV in the United States. Acetaminophen is available in over 600 combination and single-ingredient prescription and over-the-counter medicines, including tablet, caplet, orally-dosed liquid suspension, powder and suppository forms for both adults and children. Its licensor, BMS, markets intravenous formulation of acetaminophen for the treatment of acute pain and fever in Europe and several other markets outside the United States, where it is known as paracetamol and marketed under the brand name Perfalgan. The approval of OFIRMEV was supported by the results of 20 clinical trials involving 1,375 patients. Procedure types included orthopedic surgery (including total hip or knee replacement), gynecologic surgery, general surgery, ear, nose, and throat surgery, and cardiothoracic surgery. The Company competes with Acusphere, Inc., Anesiva, Inc., Cara Therapeutics, Inc., Cephalon, Inc., Durect Corporation, Javelin Pharmaceuticals, Inc., NeurogesX, Inc., Pacira Pharmaceuticals, Inc., Paion AG, St. Charles Pharmaceuticals, Inc., and TheraQuest Biosciences, LLC.